- Market Capitalization, $K 40,919
- Shares Outstanding, K 14,880
- Annual Sales, $ 37,440 K
- Annual Income, $ -3,340 K
- 60-Month Beta 0.20
- Price/Sales 1.08
- Price/Cash Flow 11.18
- Price/Book 0.88
|Period||Period Low||Period High||Performance|
| || |
-0.02 (-0.73%)since 08/24/21
| || |
-0.35 (-11.29%)since 06/24/21
| || |
-0.42 (-13.25%)since 09/24/20
Research Nester released a report titled which delivers a detailed overview of the global dexrazoxane market in terms of market segmentation by product type, by end-user and by region.
Cumberland (CPIX) delivered earnings and revenue surprises of 100.00% and 5.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
NASHVILLE, Tenn. (AP) _ Cumberland Pharmaceuticals Inc. (CPIX) on Tuesday reported second-quarter net income of $1.2 million, after reporting a loss in the same period a year earlier.
/PRNewswire/ -- (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and second quarter 2021 financial results. Net revenues from continuing operations during the quarter...
/PRNewswire/ -- announced today that it will release second quarter 2021 financial results and provide a Company update after the market closes on . A conference call and live internet webcast will be...
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
/PRNewswire/ -- Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, today released its 2020 Sustainability Report, which details the company's activities pertaining to environmental,...
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
/PRNewswire/ --Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released a series of case reports describing the effectiveness of Vibativ () in treating secondary...
United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.